Literature DB >> 12853760

Detection of intrapulmonary concentration of lopinavir in an HIV-infected patient.

Chiara Atzori, Paola Villani, Mario Regazzi, Massimiliano Maruzzi, Antonietta Cargnel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12853760     DOI： 10.1097/00002030-200307250-00022

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  9 in total

1.  Protease expression by microorganisms and its relevance to crucial physiological/pathological events.

Authors:  André Luis Souza Dos Santos
Journal:  World J Biol Chem       Date:  2011-03-26

Review 2.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.

Authors:  Keith A Rodvold; Liz Yoo; Jomy M George
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

3.  Does lopinavir really inhibit SARS-CoV-2?

Authors:  Dario Cattaneo; Dario Cattaneo; Cristina Gervasoni; Mario Corbellino; Massimo Galli; Agostino Riva; Cristina Gervasoni; Emilio Clementi; Emilio Clementi
Journal:  Pharmacol Res       Date:  2020-05-11       Impact factor: 7.658

4.  Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.

Authors:  Manuel Battegay; Parham Sendi; Catia Marzolini; Felix Stader; Marcel Stoeckle; Fabian Franzeck; Adrian Egli; Stefano Bassetti; Alexa Hollinger; Michael Osthoff; Maja Weisser; Caroline E Gebhard; Veronika Baettig; Julia Geenen; Nina Khanna; Sarah Tschudin-Sutter; Daniel Mueller; Hans H Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

5.  High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19.

Authors:  Mario Karolyi; Sara Omid; Erich Pawelka; Bernd Jilma; Thomas Stimpfl; Christian Schoergenhofer; Hermann Laferl; Tamara Seitz; Marianna Traugott; Christoph Wenisch; Alexander Zoufaly
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

Review 6.  Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.

Authors:  Nicolas Venisse; Gilles Peytavin; Stephane Bouchet; Marie-Claude Gagnieu; Rodolphe Garraffo; Romain Guilhaumou; Caroline Solas
Journal:  Antiviral Res       Date:  2020-07-10       Impact factor: 5.970

7.  Reply to the letter to the Editor "Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts".

Authors:  Nicolas Simon; Jean Claude Alvarez
Journal:  Eur J Clin Pharmacol       Date:  2020-11-26       Impact factor: 2.953

8.  Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.

Authors:  Jean Claude Alvarez; Pierre Moine; Benjamin Davido; Isabelle Etting; Djillali Annane; Islam Amine Larabi; Nicolas Simon
Journal:  Eur J Clin Pharmacol       Date:  2020-10-13       Impact factor: 2.953

9.  Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2.

Authors:  Aarzoo Thakur; Shawn Pei Feng Tan; James Chun Yip Chan
Journal:  Clin Pharmacol Ther       Date:  2020-10-06       Impact factor: 6.903
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.